Boron Molecular is a specialist fine chemicals manufacturing company providing unique building-block compounds and specialist chemistry services to the global pharmaceutical, fine chemicals and materials market.
The Company was established in 2001 and is located in Melbourne, Australia's largest biotechnology centre and a city of approximately 3.5 million people. Boron Molecular's location provides it with cost-effective access to world-class facilities and a pool of highly talented synthetic organic chemists. In October 2004 a sales and distribution office, Boron Molecular Inc., was established in Raleigh, North Carolina, to service the North American and European markets.
Boron Molecular's recipe for success is based on its significant Technology Platform emanating from its,
*Patented processes and compounds,
*Extensive experience and know-how, and
*Access to new IP through CSIRO.
Boron Molecular's Business Model is based on the generation of revenues through the provision of specialist products and services. Boron Molecular has seven patents covering various aspects of organoboron chemistry, including new processes and related composition of matter claims. Boron Molecular offers a catalogue of over 550 building-block compounds, comprising of organoboron, biaryl and cubane compounds. Boron Molecular continues to develop new intellectual property, through in-house R&D, strategic in-licensing and through collaborative associations with supply companies and clients.
Boron Molecular is committed to providing value to its customers through its ability to deliver,
*Differentiated products (unique, market-relevant building blocks),
*Reliable quality,
*Competitive pricing, and
*Excellent customer service.
United States
